Type 2 diabetes: Principles of pathogenesis and therapy

Lancet

Volumn 365, Issue 9467, 2005, Pages 1333-1346

  Stumvoll, Michael ^a   Goldstein, Barry J ^b   Van Haeften, Timon W ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LOSARTAN; METFORMIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE;

ADIPOCYTE; B LYMPHOCYTE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIAGNOSTIC TEST; DIET; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EDEMA; ENZYME ACTIVITY; EXERCISE; GASTROINTESTINAL SYMPTOM; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME; HEART FAILURE; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; TOXICITY; VARIABLE NUMBER OF TANDEM REPEAT; WEIGHT GAIN;

EID: 17044386953     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61032-X     Document Type: Conference Paper

References (156)

1. P Zimmet, KG Alberti, J Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787
2. H King, RE Aubert, WH Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
3. R Sinha, G Fisch, B Teague Prevalence of impaired glucose tolerance among children and adolescents with marked obesity N Engl J Med 346 2002 802 810
4. SS Fajans, GI Bell, KS Polonsky Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young N Engl J Med 345 2001 971 980
5. JA Maassen, LM 't Hart, E Van Essen Mitochondrial diabetes: molecular mechanisms and clinical presentation Diabetes 53 suppl 1 2004 S103 S109
6. P Pozzilli, U Di Mario Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention Diabetes Care 24 2001 1460 1467
7. M Wei, SP Gaskill, SM Haffner, MP Stern Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study Diabetes Care 21 1998 1167 1172
8. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
9. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
10. GA Nichols, HS Glauber, JB Brown Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis Diabetes Care 23 2000 1654 1659
11. World Health Organization Expert Committee Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus 1999 World Health Organization Geneva
12. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
13. J Tuomilehto, J Lindstrom, JG Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
14. DECODE Study Group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe Lancet 354 1999 617 621
15. M Pierce, H Keen, C Bradley Risk of diabetes in offspring of parents with non-insulin-dependent diabetes Diabet Med 12 1995 6 13
16. RB Tattersal, SS Fajans Prevalence of diabetes and glucose intolerance in 199 offspring of thirty-seven conjugal diabetic parents Diabetes 24 1975 452 462
17. J Kaprio, J Tuomilehto, M Koskenvuo Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland Diabetologia 35 1992 1060 1067
18. B Newman, JV Selby, MC King, C Slemenda, R Fabsitz, GD Friedman Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins Diabetologia 30 1987 763 768
19. L Henkin, RN Bergman, DW Bowden Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods Ann Epidemiol 13 2003 211 217
20. WC Hsueh, BD Mitchell, R Aburomia Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study Diabetes Care 23 2000 595 601
21. GW Mills, PJ Avery, MI McCarthy Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes Diabetologia 47 2004 732 738
22. P Poulsen, KO Kyvik, A Vaag, H Beck Nielsen Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance - a population-based twin study Diabetologia 42 1999 139 145
23. MS Freeman, MW Mansfield, JH Barrett, PJ Grant Heritability of features of the insulin resistance syndrome in a community-based study of healthy families Diabet Med 19 2002 994 999
24. M Lehtovirta, J Kaprio, C Forsblom, J Eriksson, J Tuomilehto, L Groop Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins Diabetologia 43 2000 285 293
25. RM Watanabe, T Valle, ER Hauser Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators Hum Hered 49 1999 159 168
26. RN Bergman, DJ Zaccaro, RM Watanabe Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin Diabetes 52 2003 2168 2174
27. RL Hanson, G Imperatore, KM Narayan Family and genetic studies of indices of insulin sensitivity and insulin secretion in Pima Indians Diabetes Metab Res Rev 17 2001 296 303
28. AB Jenkins, K Samaras, DG Carey, P Kelly, LV Campbell Improved indices of insulin resistance and insulin secretion for use in genetic and population studies of type 2 diabetes mellitus Twin Res 3 2000 148 151
29. SC Elbein, SJ Hasstedt, K Wegner, SE Kahn Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds J Clin Endocrinol Metab 84 1999 1398 1403
30. Y Hong, SJ Weisnagel, T Rice Familial resemblance for glucose and insulin metabolism indices derived from an intravenous glucose tolerance test in Blacks and Whites of the HERITAGE Family Study Clin Genet 60 2001 22 30
31. H Sakul, R Pratley, L Cardon, E Ravussin, D Mott, C Bogardus Familiality of physical and metabolic characteristics that predict the development of non-insulin-dependent diabetes mellitus in Pima Indians Am J Hum Genet 60 1997 651 656
32. H Beck-Nielsen, A Vaag, P Poulsen, M Gaster Metabolic and genetic influence on glucose metabolism in type 2 diabetic subjects - experiences from relatives and twin studies Best Pract Res Clin Endocrinol Metab 17 2003 445 467
33. CN Hales, DJ Barker Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis Diabetologia 35 1992 595 601
34. AT Hattersley, JE Tooke The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease Lancet 353 1999 1789 1792
35. RN Bergman Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach Diabetes 38 1989 1512 1527
36. C Weyer, C Bogardus, DM Mott, RE Pratley The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 104 1999 787 794
37. M Stumvoll, PA Tataranni, N Stefan, B Vozarova, C Bogardus Glucose allostasis Diabetes 52 2003 903 909
38. S Dinneen, J Gerich, R Rizza Carbohydrate metabolism in non-insulin-dependent diabetes mellitus N Engl J Med 327 1992 707 713
39. C Weyer, C Bogardus, RE Pratley Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance Diabetes 48 1999 2197 2203
40. C Meyer, M Stumvoll, V Nadkarni, J Dostou, A Mitrakou, J Gerich Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus J Clin Invest 102 1998 619 624
41. G Boden Role of fatty acids in the pathogenesis of insulin resistance and NIDDM Diabetes 46 1997 3 10
42. E Danforth Jr Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 26 2000 13
43. J Machann, H Haring, F Schick, M Stumvoll Intramyocellular lipids and insulin resistance Diabetes Obes Metab 6 2004 239 248
44. A Seppala-Lindroos, S Vehkavaara, AM Hakkinen Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men J Clin Endocrinol Metab 87 2002 3023 3028
45. M Bajaj, S Suraamornkul, T Pratipanawatr Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes Diabetes 52 2003 1364 1370
46. JC Bruning, MD Michael, JN Winnay A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance Mol Cell 2 1998 559 569
47. MD Michael, RN Kulkarni, C Postic Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction Mol Cell 6 2000 87 97
48. M Bluher, BB Kahn, CR Kahn Extended longevity in mice lacking the insulin receptor in adipose tissue Science 299 2003 572 574
49. JC Bruning, D Gautam, DJ Burks Role of brain insulin receptor in control of body weight and reproduction Science 289 2000 2122 2125
50. RN Kulkarni, JC Bruning, JN Winnay, C Postic, MA Magnuson, CR Kahn Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes Cell 96 1999 329 339
51. Y Kido, J Nakae, D Accili Clinical review 125: The insulin receptor and its cellular targets J Clin Endocrinol Metab 86 2001 972 979
52. MF White IRS proteins and the common path to diabetes Am J Physiol Endocrinol Metab 283 2002 E413 E422
53. Y Zick Insulin resistance: a phosphorylation-based uncoupling of insulin signaling Trends Cell Biol 11 2001 437 441
54. BJ Goldstein Protein-tyrosine phosphatases and the regulation of insulin action D LeRoith SI Taylor JM Olefsky Diabetes mellitus: a fundamental and clinical text 2003 Lippincott Philadelphia 255 268
55. R Zhande, JJ Mitchell, J Wu, XJ Sun Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1 Mol Cell Biol 22 2002 1016 1026
56. L Rui, M Yuan, D Frantz, S Shoelson, MF White SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 J Biol Chem 277 2002 42394 42398
57. MW Rajala, PE Scherer Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis Endocrinology 144 2003 3765 3773
58. E Ravussin, SR Smith Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus Ann N Y Acad Sci 967 2002 363 378
59. G Boden, GI Shulman Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and b-cell dysfunction Eur J Clin Invest 32 suppl 3 2002 14 23
60. GI Shulman Cellular mechanisms of insulin resistance J Clin Invest 106 2000 171 176
61. ME Griffin, MJ Marcucci, GW Cline Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade Diabetes 48 1999 1270 1274
62. SI Itani, NB Ruderman, F Schmieder, G Boden Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha Diabetes 51 2002 2005 2011
63. Z Gao, X Zhang, A Zuberi Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes Mol Endocrinol 18 2004 2024 2034
64. GS Hotamisligil Molecular mechanisms of insulin resistance and the role of the adipocyte Int J Obes Relat Metab Disord 24 2000 S23 S27
65. DE Moller Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes Trends Endocrinol Metab 11 2000 212 217
66. JJ Senn, PJ Klover, IA Nowak Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes J Biol Chem 278 2003 13740 13746
67. DL Krebs, DJ Hilton A new role for SOCS in insulin action. Suppressor of cytokine signaling Sci STKE 2003 2003 E6
68. BJ Goldstein, R Scalia Adiponectin: a novel adipokine linking adipocytes and vascular function J Clin Endocrinol Metab 89 2004 2563 2568
69. T Yamauchi, J Kamon, Y Minokoshi Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase Nat Med 8 2002 1288 1295
70. E Tomas, TS Tsao, AK Saha Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation Proc Natl Acad Sci USA 99 2002 16309 16313
71. X Wu, H Motoshima, K Mahadev, TJ Stalker, R Scalia, BJ Goldstein Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes Diabetes 52 2003 1355 1363
72. NB Ruderman, JM Cacicedo, S Itani Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes Biochem Soc Trans 31 2003 202 206
73. G Zhou, R Myers, Y Li Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 2001 1167 1174
74. MH Zou, SS Kirkpatrick, BJ Davis Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo: Role of mitochondrial reactive nitrogen species J Biol Chem 279 2004 43940 43951
75. LG Fryer, A Parbu-Patel, D Carling The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways J Biol Chem 277 2002 25226 25232
76. M Karin, M Delhase The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling Semin Immunol 12 2000 85 98
77. MJ Yin, Y Yamamoto, RB Gaynor The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta Nature 396 1998 77 80
78. JK Kim, YJ Kim, JJ Fillmore Prevention of fat-induced insulin resistance by salicylate J Clin Invest 108 2001 437 446
79. M Yuan, N Konstantopoulos, J Lee Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta Science 293 2001 1673 1677
80. SE Shoelson, J Lee, M Yuan Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance Int J Obes Relat Metab Disord 27 suppl 3 2003 S49 S52
81. PJ Havel Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin Curr Opin Lipidol 13 2002 51 59
82. KE Wellen, GS Hotamisligil Obesity-induced inflammatory changes in adipose tissue J Clin Invest 112 2003 1785 1788
83. DE Kelley, J He, EV Menshikova, VB Ritov Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes Diabetes 51 2002 2944 2950
84. KF Petersen, S Dufour, D Befroy, R Garcia, GI Shulman Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes N Engl J Med 350 2004 664 671
85. ME Patti, AJ Butte, S Crunkhorn Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1 Proc Natl Acad Sci USA 100 2003 8466 8471
86. VK Mootha, CM Lindgren, KF Eriksson PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes Nat Genet 34 2003 267 273
87. JE Gerich The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity Endocr Rev 19 1998 491 503
88. TW Van Haeften, W Pimenta, A Mitrakou Disturbances in beta-cell function in impaired fasting glycemia Diabetes 51 suppl 1 2002 S265 S270
89. RC Bonadonna, M Stumvoll, A Fritsche Altered homeostatic adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function Diabetes 52 2003 470 480
90. RP Robertson, J Harmon, PO Tran, Y Tanaka, H Takahashi Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection Diabetes 52 2003 581 587
91. H Yki-Järvinen Glucose toxicity Endocr Rev 13 1992 415 431
92. TM Wallace, DR Matthews Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes Diabet Med 19 2002 465 469
93. RP Robertson, J Harmon, PO Tran, V Poitout Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes Diabetes 53 suppl 1 2004 S119 S124
94. J Janson, RH Ashley, D Harrison, S McIntyre, PC Butler The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles Diabetes 48 1999 491 498
95. RL Hull, GT Westermark, P Westermark, SE Kahn Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes J Clin Endocrinol Metab 89 2004 3629 3643
96. NG Knowles, MA Landchild, WY Fujimoto, SE Kahn Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes Diabetes Care 25 2002 292 297
97. H Parikh, L Groop Candidate genes for type 2 diabetes Rev Endocr Metab Disord 5 2004 151 176
98. KE Lohmueller, CL Pearce, M Pike, ES Lander, JN Hirschhorn Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease Nat Genet 33 2003 177 182
99. JM Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists J Clin Invest 106 2000 467 472
100. K Schoonjans, J Auwerx Thiazolidinediones: an update Lancet 355 2000 1008 1010
101. J Auwerx PPARgamma, the ultimate thrifty gene Diabetologia 42 1999 1033 1049
102. D Altshuler, JN Hirschhorn, M Klannemark The common PPARg Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes Nat Gen 26 2000 76 80
103. A Memisoglu, FB Hu, SE Hankinson Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes Diabetes Care 26 2003 2915 2917
104. SS Deeb, L Fajas, M Nemoto A Pro12Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity Nat Genet 20 1998 284 287
105. J Ek, G Andersen, SA Urhammer Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant Caucasians Diabetologia 44 2001 1170 1176
106. YL Muller, C Bogardus, BA Beamer, AR Shuldiner, LJ Baier A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians Diabetes 52 2003 1864 1871
107. M Stumvoll, H Häring The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor γ Diabetes 51 2002 2341 2347
108. O Porzio, M Federici, ML Hribal The Gly972®Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells J Clin Invest 104 1999 357 364
109. M Stumvoll, A Fritsche, A Volk The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose tolerant humans Diabetes 50 2001 882 885
110. J Ek, G Andersen, SA Urhammer Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus Diabetologia 44 2001 2220 2226
111. AL Gloyn, MN Weedon, KR Owen Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6·2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes Diabetes 52 2003 568 572
112. JC Florez, N Burtt, PI de Bakker Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region Diabetes 53 2004 1360 1368
113. CJ Rhodes, MF White Molecular insights into insulin action and secretion Eur J Clin Invest 32 suppl 3 2002 3 13
114. MI McCarthy Growing evidence for diabetes susceptibility genes from genome scan data Curr Diab Rep 3 2003 159 167
115. NJ Cox Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene Hum Mol Genet 10 2001 2301 2305
116. Y Horikawa, N Oda, NJ Cox Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus Nat Genet 26 2000 163 175
117. H Ma, C Fukiage, YH Kim Characterization and expression of calpain 10. A novel ubiquitous calpain with nuclear localization J Biol Chem 276 2001 28525 28531
118. K Suzuki, S Hata, Y Kawabata, H Sorimachi Structure, activation, and biology of calpain Diabetes 53 2004 S12 S18
119. SK Rasmussen, SA Urhammer, L Berglund Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians Diabetes 51 2002 3561 3567
120. Y Horikawa, N Oda, L Yu Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese J Clin Endocrinol Metab 88 2003 244 247
121. JC Evans, TM Frayling, PG Cassell Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom Am J Hum Genet 69 2001 544 552
122. L Bosque-Plata, CA Aguilar-Salinas, MT Tusie-Luna Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population Mol Genet Metab 81 2004 122 126
123. Y Song, T Niu, JE Manson, DJ Kwiatkowski, S Liu Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies Am J Hum Genet 74 2004 208 222
124. MN Weedon, PE Schwarz, Y Horikawa Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility Am J Hum Genet 73 2003 1208 1212
125. LJ Baier, PA Permana, X Yang A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance J Clin Invest 106 2000 R69 R73
126. SK Sreenan, YP Zhou, K Otani Calpains play a role in insulin secretion and action Diabetes 50 2001 2013 2020
127. D Tripathy, KF Eriksson, M Orho-Melander, J Fredriksson, G Ahlqvist, L Groop Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes Diabetologia 47 2004 782 793
128. K Silander, KL Mohlke, LJ Scott Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes Diabetes 53 2004 1141 1149
129. KK Ong, DI Phillips, C Fall The insulin gene VNTR, type 2 diabetes and birth weight Nat Genet 21 1999 262 263
130. SJ Huxtable, PJ Saker, L Haddad Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles Diabetes 49 2000 126 130
131. H Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106 1118
132. JM Ye, N Dzamko, ME Cleasby Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin Diabetologia 47 2004 1306 1313
133. T Meriden Progress with thiazolidinediones in the management of type 2 diabetes mellitus Clin Ther 26 2004 177 190
134. D Einhorn, VR Aroda, RR Henry Glitazones and the management of insulin resistance: what they do and how might they be used Endocrinol Metab Clin North Am 33 2004 595 616
135. RW Nesto, D Bell, RO Bonow Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 108 2003 2941 2948
136. CJ Bailey, RC Turner Metformin N Engl J Med 334 1996 574 579
137. K Cusi, A Consoli, RA DeFronzo Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 81 1996 4059 4067
138. JC Mamputu, NF Wiernsperger, G Renier Antiatherogenic properties of metformin: the experimental evidence Diabetes Metab 29 2003 6S71 6S76
139. JL Chiasson, R Gomis, M Hanefeld, RG Josse, A Karasik, M Laakso The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus Diabetes Care 21 1998 1720 1725
140. M Rendell The role of sulphonylureas in the management of type 2 diabetes mellitus Drugs 64 2004 1339 1358
141. G Schernthaner, A Grimaldi, U Di Mario GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients Eur J Clin Invest 34 2004 535 542
142. P Dandona, A Aljada, S Dhindsa, R Garg Insulin as an anti-inflammatory and antiatherosclerotic hormone Clin Cornerstone 4 2003 S13 S20
143. CF Deacon Therapeutic strategies based on glucagon-like peptide 1 Diabetes 53 2004 2181 2189
144. G Liu Technology evaluation: ISIS-113715, Isis Curr Opin Mol Ther 6 2004 331 336
145. Eckel RH, Grundy SM, Zimmer PZ. The metabolic syndrome. Lancet (in press).
146. JA Beckman, MA Creager, P Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
147. HOPE Study Group Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet 355 2000 253 259
148. CE Mogensen, S Neldam, I Tikkanen Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 2000 1440 1444
149. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
150. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
151. SM Grundy, GL Vega, ME McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niacin trial Arch Intern Med 162 2002 1568 1576
152. JA Colwell Aspirin therapy in diabetes Diabetes Care 27 suppl 1 2004 S72 S73
153. XR Pan, GW Li, YH Hu Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study Diabetes Care 20 1997 537 544
154. TA Buchanan, AH Xiang, RK Peters Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women Diabetes 51 2002 2796 2803
155. JL Chiasson, RG Josse, R Gomis, M Hanefeld, A Karasik, M Laakso Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 359 2002 2072 2077
156. R Di Paola, L Frittitta, G Miscio A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance Am J Hum Genet 70 2002 806 812